Table.

Characteristics of included studies. All studies were double blind, double dummy,^* parallel group, randomised controlled trials except where indicated

Study	No of participants with seasonal allergic rhinitis	Age range (mean age)	Interventions	Outcomes
Munch10	61	16-56 (29)	Budesonide 400 μg	Nasal symptoms
			Dexchlorpheniramine 12 mg	Eye symptoms
Beswick11	49	14-64 (28)	Beclomethasone 400 μg	Nasal symptoms
			Terfenadine 120 mg	Eye symptoms
				Global rating
Wood12	74	12-75 (28)	Beclomethasone 400 μg	Nasal symptoms
			Astemizole 10 mg	Eye symptoms
Lancer13	18	Not reported	Beclomethasone 400 μg	Global rating
			Terfenadine 120 mg	Nasal resistance
Juniper14	90	18-70 (41)	Beclomethasone 400 μg	Nasal symptoms
			Astemizole 10 mg	Eye symptoms
Robinson†15	20	15-58 (31)	Beclomethasone 400 μg	Nasal symptoms
			Terfenadine 120 mg	Eye symptoms
Bunnag16	69‡	16-70 (30)	Budesonide 200 μg	Nasal symptoms
			Astemizole 10 mg
Darnell17	214	13-69 (28)	Fluticasone 200 μg	Nasal symptoms
			Terfenadine 120 mg	Eye symptoms
				Global rating
Simpson18	143	>15 (27)	Budesonide 400 μg	Nasal symptoms
			Terfenadine 120 mg	Eye symptoms
Van Bavel19	232	>12 (40)	Fluticasone 200 μg	Nasal symptoms
			Terfenadine 120 mg	Global rating
Schoenwetter20	298	>12 (31)	Triamcinolone 220 μg	Nasal symptoms
			Loratadine 10 mg	Eye symptoms
Bernstein21	239	Adults (36)	Triamcinolone 220 μg	Nasal symptoms
			Astemizole 10 mg	Eye symptoms
				Global rating
Bronsky22	348	>12 (30)	Fluticasone 200 μg	Nasal symptoms
			Terfenadine 120 mg	Global rating
				Nasal resistance
Brooks23	60	Not reported	Beclomethasone 336 μg	Nasal symptoms
			Loratadine 10 mg	Eye symptoms
				Global rating
Géhanno24	114	13-80 (39)	Fluticasone 200 μg	Nasal symptoms
			Loratadine 10 mg	Global rating
Vervloet25	238	12-75 (29)	Fluticasone 200 μg	Nasal symptoms
			Cetirizine 10 mg

^*All patients took tablets and used nasal sprays, but only one preparation was active. 

^†Double blind double dummy crossover randomised controlled trial. 

^‡Participants had perennial allergic rhinitis.